Inhibikase Therapeutics's total assets for Q1 2025 were $94.28M, a decrease of -4.38% from the previous quarter. IKT total liabilities were $8.55M for the fiscal quarter, a 129.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.